Mereo Biopharma Group Plc - ADR

NASDAQ:MREO  
3.37
+0.07 (+2.12%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Mereo Biopharma Group Plc - ADR Stock, NASDAQ:MREO

1 Cavendish Place, 4th Floor, London, Greater London W1G 0QF
Phone: +44.333.023.7300
Number of Employees: 38

Description

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.